Publications en collaboration avec des chercheurs de Oregon Medical Research Center (3)

2017

  1. Secukinumab demonstrates greater sustained improvements in daily activities and personal relationships than ustekinumab in patients with moderate-to-severe plaque psoriasis: 52-week results from the CLEAR study

    Journal of the European Academy of Dermatology and Venereology, Vol. 31, Núm. 10, pp. 1693-1699

  2. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to-severe plaque psoriasis up to 1 year: Results from the CLEAR study

    Journal of the American Academy of Dermatology, Vol. 76, Núm. 1, pp. 60-69.e9

2015

  1. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial

    Journal of the American Academy of Dermatology, Vol. 73, Núm. 3, pp. 400-409